Drug-mediated inhibition of MET activation

European Bioinformatics Institute, New York University Langone Medical Center, Ontario Institute for Cancer Research, Oregon Health and Science University. The contents of this document may be freely copied and distributed in any media, provided the authors, plus the institutions, are credited, as stated under the terms of Creative Commons Attribution 4.0 International (CC BY 4.0) License. For more information see our license. This is just an excerpt of a full-length report for this pathway. To access the complete report, please download it at the Reactome Textbook. 18/11/2022

[1]  O. De Wever,et al.  OMO-1 reduces progression and enhances cisplatin efficacy in a 4T1-based non-c-MET addicted intraductal mouse model for triple-negative breast cancer , 2021, NPJ breast cancer.

[2]  L. Trusolino,et al.  Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapy , 2018, Nature Reviews Cancer.

[3]  Henning Hermjakob,et al.  Reactome graph database: Efficient access to complex pathway data , 2018, PLoS Comput. Biol..

[4]  L. Stein,et al.  Reactome pathway analysis: a high-performance in-memory approach , 2017, BMC Bioinformatics.

[5]  Natalie de Jonge,et al.  Depleting MET-Expressing Tumor Cells by ADCC Provides a Therapeutic Advantage over Inhibiting HGF/MET Signaling. , 2015, Cancer research.

[6]  Ying Tang,et al.  LY2875358, a Neutralizing and Internalizing Anti-MET Bivalent Antibody, Inhibits HGF-Dependent and HGF-Independent MET Activation and Tumor Growth , 2014, Clinical Cancer Research.

[7]  C.-H. Kim,et al.  Met degradation by SAIT301, a Met monoclonal antibody, reduces the invasion and migration of nasopharyngeal cancer cells via inhibition of EGR-1 expression , 2014, Cell Death and Disease.

[8]  J. M. Lee,et al.  Cbl-independent degradation of Met: ways to avoid agonism of bivalent Met-targeting antibody , 2014, Oncogene.

[9]  Henning Hermjakob,et al.  The Reactome pathway knowledgebase , 2013, Nucleic Acids Res..

[10]  G. V. Vande Woude,et al.  Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent , 2013, Proceedings of the National Academy of Sciences.

[11]  A. Bardelli,et al.  Tivantinib (ARQ197) Displays Cytotoxic Activity That Is Independent of Its Ability to Bind MET , 2013, Clinical Cancer Research.

[12]  S. Jeay,et al.  ARQ 197, a Novel and Selective Inhibitor of the Human c-Met Receptor Tyrosine Kinase with Antitumor Activity , 2010, Molecular Cancer Therapeutics.

[13]  J. Fargnoli,et al.  Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamily. , 2009, Journal of medicinal chemistry.

[14]  J. Christensen,et al.  A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase. , 2003, Cancer research.